Joseph Young Sells 3,117 Shares of Vera Therapeutics (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Joseph Young sold 3,117 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $130,851.66. Following the completion of the sale, the senior vice president directly owned 64,722 shares of the company’s stock, valued at approximately $2,717,029.56. The trade was a 4.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Vera Therapeutics Stock Up 1.6%

VERA stock opened at $42.35 on Friday. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $56.05. The business’s 50 day simple moving average is $46.53 and its 200 day simple moving average is $35.35. The company has a current ratio of 12.21, a quick ratio of 12.21 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $2.97 billion, a PE ratio of -10.61 and a beta of 1.16.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.34) by ($0.05). During the same period in the previous year, the company earned ($0.72) EPS. As a group, research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

Vera Therapeutics News Summary

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: FDA priority review and NEJM/ASN recognition for atacicept — Vera reported positive Phase 3 ORIGIN‑3 data for atacicept in IgA nephropathy that were presented at ASN Kidney Week and published in the New England Journal of Medicine. The FDA has granted priority review for the atacicept BLA with a PDUFA date of July 7, 2026, and the company expects a potential U.S. commercial launch in mid‑2026. Management also said recent 2025 equity and debt financings leave the company well‑capitalized into and beyond approval and launch. Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
• Neutral Sentiment: Financials/earnings update — Vera released FY‑2025 results and quarterly EPS figures; one report shows EPS of ($1.39) for the quarter (slightly missing consensus by ~$0.05). The results highlight continued operating losses but the company emphasizes runway provided by recent financings. Investors will focus on how close the company is to commercialization economics once/if atacicept is approved. View Press Release
• Negative Sentiment: Concentrated insider selling — multiple senior executives (including the CEO, CFO, COO and other officers) sold shares on Feb 23 at roughly $42/share (CEO Marshall Fordyce sold ~16,925 shares; other officers also reduced holdings). Such clustered insider sales can prompt investor caution and short‑term selling pressure despite the regulatory progress. Vera Therapeutics Insider Sells

Institutional Investors Weigh In On Vera Therapeutics

Several institutional investors have recently made changes to their positions in VERA. Capricorn Fund Managers Ltd acquired a new position in Vera Therapeutics during the third quarter valued at approximately $13,097,000. Swedbank AB bought a new position in shares of Vera Therapeutics in the 3rd quarter valued at $1,453,000. Squarepoint Ops LLC increased its stake in shares of Vera Therapeutics by 232.0% in the 2nd quarter. Squarepoint Ops LLC now owns 57,519 shares of the company’s stock valued at $1,355,000 after purchasing an additional 40,196 shares during the last quarter. Bollard Group LLC acquired a new position in shares of Vera Therapeutics during the 2nd quarter worth $1,509,000. Finally, SG Americas Securities LLC bought a new stake in shares of Vera Therapeutics during the 3rd quarter worth $911,000. 99.21% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Vera Therapeutics in a report on Wednesday, November 26th. JPMorgan Chase & Co. decreased their target price on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a research report on Friday, December 19th. Evercore lifted their price target on Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a research note on Friday, December 5th. Finally, Bank of America upped their price objective on Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a report on Friday, December 19th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $78.80.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.